Drug Utilization Evaluation of Lorazepam in Alcohol Withdrawal Syndrome Patients: A Secondary Care Teaching Hospital Based Study
Background: Drug utilization evaluation is an important parameter for the safe, effective and rational use of medications in medical care. Alcoholism results in abundant cases of alcohol withdrawal which can prove to be life-threatening if untreated, lorazepam is a drug of choice for Alcohol Withdrawal Syndrome and requires close monitoring as its over-dosing or under-dosing is common in case of withdrawal. Objective: ensures the safe and rational use of Lorazepam in the management of Alcohol Withdrawal Syndrome. Materials and Method: This prospective, observational study was conducted among alcoholic patients admitted in the KC General Hospital, Karnataka, India. Baseline data for Clinical Institute Withdrawal Assessment for Alcohol revised scale (CIWA-Ar) was collected on the day of admission and the response to lorazepam treatment was recorded using the same with respect to the baseline data every 12th hourly after the initial administration until withdrawn. Results: Statistical analysis for 72 patients was done using ANOVA to calculate the overall progression of the syndrome with treatment. Among 72 patients 94.44% were male and 5.55% were female. The mean age of patients reported with AWS was found to be 44.90 years. A significant CIWA-Ar score reduction was observed with a p-value of <0.0001. Conclusion: Our study revealed a strong predominance of male patients with alcohol withdrawal syndrome, where maximum patients started consuming alcohol before the age of 20 years. After the administration of lorazepam, a significant CIWA-Ar score reduction was observed.
Keywords: Alcohol Withdrawal Syndrome, CIWA-Ar scale, Drug utilization evaluation, Lorazepam.
2. Jesse S, Brathen G, Ferrara M, Keindl M, Ben-Menachem E, Tanasescu R et al. Alcohol withdrawal syndrome: mechanisms, manifestations and management. Acta Neurol Scand. 2017; 135(1):4-16.
3. Kolasani B, Sasidharan P, CM D, Jayabal P, Rajaseharan A. Prescribing pattern of drugs in patients with alcoholic liver disease in a tertiary care teaching hospital. Natl J Physiol, Pharm Pharmacol. 2017; 7(5):538-44.
4. Wetterling T, Driessen M, Kanitz DR, Junghanns K. The severity of Alcohol Withdrawal is not age dependent. Alcohol alcohol. 2001; 36(1):75-8.
5. Forrest E, Ahmed A, Benson G. The Management of Alcohol Withdrawal in Patients with advanced Liver Disease. Glasgow Royal Infirmary. 2013; 62(1):A83.
6. McKeon A, Frye AM, Delanty N. The Alcohol Withdrawal syndrome. J NuerolNeurosung Psychiatry. 2008; 79(8):854-62.
7. Hughes JR. Alcohol withdrawal seizures. Epilepsy Behav. 2009; 15(2):92-7.
8. Rogawski MA. Update on the neurobiology of alcohol withdrawal seizures. Epilepsy curr. 2005; 5(6):225-30.
9. Kovacs GL. Natriuretic peptides in alcohol withdrawal: central and peripheral mechanisms. Curr Med Chem. 2003; 10:2559-76.
10. S, Bharadwaj B. Clinical management of alcohol withdrawal: A systematic review. Ind Psychiatry J. 2013 Jul-Dec; 22(2):100-8.
11. Gortney SJ, Raub NJ, Patel P, Kokoska L, Hannawa M, Argyris A. Alcohol withdrawal syndrome in medical patients. Cleve Clin J Med. 2016 Jan; 83(1):67-79.
12. Mayo-smith MF, MD, Lee H.Beecher, Timothy L. Fischer, Gorelick, Jeanette L. Guillaume et al. Management of Withdrawal Delirium. N Eng J Med. 2004 July; 164(6):1405-12.
13. Sachdeva A, Choudhary M, Chandra M. Alcohol withdrawal syndrome: benzodiazepines and beyond. Journal of clinical and diagnostic research. 2015 Sep; 9(9):1-7.
14. Chad A. Asplund, Jacob W, Aaronson DO, Hadassah E. 3 regimens for alcohol withdrawal and detoxification. Fam Pract. 2004 Jul; 53(7):545-54.
15. Prasad, Manya; Krishnan, Pudukode R.; Sequeira, Reginald; Al-Roomi, Khaldoon (2014-09-10). "Anticonvulsant therapy for status epilepticus". The Cochrane Database of Systematic Reviews. 2005 Oct;(4):1469-93
16. Leggio L, Lee M. Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. Am J Med.2017; 130(2):124-34.
17. Rang PH, Dale MM, Ritter MJ, Moore KP. Anxiolytic and hypnotic drugs. Pharmacology. 2003; 5:515-23.
18. Sullivan J, Sykora K, Schneiderman J, Naranjo C, Sellers E. Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict.1989; 84(11):1353-57.
19. Vrdoljak D, Markovic B.B, Puljak L, Lalic I. D et al. Lifestyle intervention in general practice for physical activity, smoking, alcohol consumption and diet in elderly: A randomised controlled trial. Arch. Gerontol. Geriatr. 2014 Jan-Feb; 58(1):160-9.
20. Rajmohan V. An open label comparison of chlordiazepoxide and lorazepam in alcohol withdrawal. JEMDS. 2013 Jun; 2(25):4609-13.
21. Perry E. Inpatient Management of Acute Alcohol Withdrawal Syndrome. CNS Drugs 2014; 28(5):401-10.
22. Holbrook MA, Crowther R, Lottery A, Cheng C, King D. Diagnosis and management of acute alcohol withdrawal. CMAJ. 1999;160(5):675-80
23. Manikant S, Tripathi MB, Chavan SB. Utility of CIWA-A in alcohol withdrawal assessment. Indian J Psychiat. 1992; 34(4):347-5
24. Williams D, Lewis J, McBride A. A comparison of rating scales for alcohol withdrawal syndrome. Alcohol and alcoholism. 2001; 36(2):104-8.
25. Sachdeva P D. Drug utilization studies - scope and future pr. Ijpbr. 2010; 1(1):11-17.
26. Robert N. Managed care pharmacy practice, 2nd ed. USA: Jones & Bartlett Learning; 2008.
27. Sacristan AJ, Soto J. Drug utilization studies as tools in health economics. PharmacoEconomics. 1994; 5(4):299-312.
28. World Health Organization. Global status report on alcohol and health. Switzerland: World Health Organization; 2011
29. Grant FB, Dawson AD. Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence. J Subst Abus Alcohol. 1997; 9:103-10.
30. Makdissi R, Stewart HS. Care for hospitalized patients with unhealthy alcohol use: a narrative review. Addict Sci Clin Pract. 2013; 8(11):1-10.
31. Bayard M, McIntyre J, Hill KR, Woodside J jr. Alcohol Withdrawal syndrome. Am Fam Physician. 2004 Mar; 69(6):1443-50.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).